IL-13 in asthma and allergic disease: Asthma phenotypes and targeted therapies

Wills-Karp, 1998, Interleukin-13: central mediator of allergic asthma, Science, 282, 2258, 10.1126/science.282.5397.2258 Grunig, 1998, Requirement for IL-13 independently of IL-4 in experimental asthma, Science, 282, 2261, 10.1126/science.282.5397.2261 Bottema, 2010, Interleukin 13 and interleukin 4 receptor-alpha polymorphisms in rhinitis and asthma, Int Arch Allergy Immunol, 153, 259, 10.1159/000314366 Kuperman, 2008, Interleukin-4, interleukin-13, signal transducer and activator of transcription factor 6, and allergic asthma, Curr Mol Med, 8, 384, 10.2174/156652408785161032 Brightling, 2010, Interleukin-13: prospects for new treatments, Clin Exp Allergy, 40, 42 Kraft, 2011, Asthma phenotypes and interleukin-13—moving closer to personalized medicine, N Engl J Med, 365, 1141, 10.1056/NEJMe1108666 Locksley, 2010, Asthma and allergic inflammation, Cell, 140, 777, 10.1016/j.cell.2010.03.004 Van der Pouw Kraan, 1998, The role of IL-13 in IgE synthesis by allergic asthma patients, Clin Exp Immunol, 111, 129, 10.1046/j.1365-2249.1998.00471.x Besnard, 2011, IL-33-activated dendritic cells are critical for allergic airway inflammation, Eur J Immunol, 41, 1675, 10.1002/eji.201041033 Smithgall, 2008, IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells, Int Immunol, 20, 1019, 10.1093/intimm/dxn060 Ikeda, 2003, Mast cells produce interleukin-25 upon Fc epsilon RI-mediated activation, Blood, 101, 3594, 10.1182/blood-2002-09-2817 Wang, 2007, IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLP-DC-activated Th2 memory cells, J Exp Med, 204, 1837, 10.1084/jem.20070406 Bartemes, 2012, IL-33-responsive lineage- CD25+ CD44(hi) lymphoid cells mediate innate type 2 immunity and allergic inflammation in the lungs, J Immunol, 188, 1503, 10.4049/jimmunol.1102832 Mjosberg, 2011, Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161, Nat Immunol, 12, 1055, 10.1038/ni.2104 Pope, 2001, IL-13 induces eosinophil recruitment into the lung by an IL-5- and eotaxin-dependent mechanism, J Allergy Clin Immunol, 108, 594, 10.1067/mai.2001.118600 Martinez-Nunez, 2011, The interleukin 13 (IL-13) pathway in human macrophages is modulated by microRNA-155 via direct targeting of interleukin 13 receptor alpha1 (IL13Ralpha1), J Biol Chem, 286, 1786, 10.1074/jbc.M110.169367 Ramirez-Icaza, 2004, Th2 cytokines IL-4 and IL-13 downregulate paxillin expression in bronchial airway epithelial cells, J Clin Immunol, 24, 426, 10.1023/B:JOCI.0000029111.27168.c6 Zhu, 1999, Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production, J Clin Invest, 103, 779, 10.1172/JCI5909 Chibana, 2008, IL-13 induced increases in nitrite levels are primarily driven by increases in inducible nitric oxide synthase as compared with effects on arginases in human primary bronchial epithelial cells, Clin Exp Allergy, 38, 936, 10.1111/j.1365-2222.2008.02969.x Kuperman, 2002, Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma, Nat Med, 8, 885, 10.1038/nm734 LaPorte, 2008, Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system, Cell, 132, 259, 10.1016/j.cell.2007.12.030 Goenka, 2011, Transcriptional regulation by STAT6, Immunol Res, 50, 87, 10.1007/s12026-011-8205-2 Ingram, 2006, Opposing actions of Stat1 and Stat6 on IL-13-induced up-regulation of early growth response-1 and platelet-derived growth factor ligands in pulmonary fibroblasts, J Immunol, 177, 4141, 10.4049/jimmunol.177.6.4141 Wang, 2004, STAT-1 is activated by IL-4 and IL-13 in multiple cell types, Mol Immunol, 41, 873, 10.1016/j.molimm.2004.04.027 Hecker, 2010, Dysregulation of the IL-13 receptor system: a novel pathomechanism in pulmonary arterial hypertension, Am J Respir Crit Care Med, 182, 805, 10.1164/rccm.200909-1367OC Cho, 2006, Role of early growth response-1 (Egr-1) in interleukin-13-induced inflammation and remodeling, J Biol Chem, 281, 8161, 10.1074/jbc.M506770200 Chen, 2009, IL-13R alpha 2 membrane and soluble isoforms differ in humans and mice, J Immunol, 183, 7870, 10.4049/jimmunol.0901028 O'Toole, 2008, A novel and sensitive ELISA reveals that the soluble form of IL-13R-alpha2 is not expressed in plasma of healthy or asthmatic subjects, Clin Exp Allergy, 38, 594, 10.1111/j.1365-2222.2007.02921.x Donaldson, 1998, The murine IL-13 receptor alpha 2: molecular cloning, characterization, and comparison with murine IL-13 receptor alpha 1, J Immunol, 161, 2317, 10.4049/jimmunol.161.5.2317 Caput, 1996, Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor alpha chain, J Biol Chem, 271, 16921, 10.1074/jbc.271.28.16921 Zheng, 2008, IL-13 receptor alpha2 selectively inhibits IL-13-induced responses in the murine lung, J Immunol, 180, 522, 10.4049/jimmunol.180.1.522 Andrews, 2006, IL-13 receptor alpha 2: a regulator of IL-13 and IL-4 signal transduction in primary human fibroblasts, J Allergy Clin Immunol, 118, 858, 10.1016/j.jaci.2006.06.041 Ingram, 2011, Airway fibroblasts in asthma manifest an invasive phenotype, Am J Respir Crit Care Med, 183, 1625, 10.1164/rccm.201009-1452OC Fichtner-Feigl, 2006, IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis, Nat Med, 12, 99, 10.1038/nm1332 Mandal, 2010, Elevated IL-13Ralpha2 in intestinal epithelial cells from ulcerative colitis or colorectal cancer initiates MAPK pathway, Inflamm Bowel Dis, 16, 753, 10.1002/ibd.21133 Fujisawa, 2009, A novel role of interleukin-13 receptor alpha2 in pancreatic cancer invasion and metastasis, Cancer Res, 69, 8678, 10.1158/0008-5472.CAN-09-2100 Lee, 2001, Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1), J Exp Med, 194, 809, 10.1084/jem.194.6.809 Temann, 2007, IL9 leads to airway inflammation by inducing IL13 expression in airway epithelial cells, Int Immunol, 19, 1, 10.1093/intimm/dxl117 Prieto, 2000, Increased interleukin-13 mRNA expression in bronchoalveolar lavage cells of atopic patients with mild asthma after repeated low-dose allergen provocations, Respir Med, 94, 806, 10.1053/rmed.2000.0826 Huang, 1995, IL-13 expression at the sites of allergen challenge in patients with asthma, J Immunol, 155, 2688, 10.4049/jimmunol.155.5.2688 Lordan, 2002, Cooperative effects of Th2 cytokines and allergen on normal and asthmatic bronchial epithelial cells, J Immunol, 169, 407, 10.4049/jimmunol.169.1.407 Richter, 2001, The contribution of interleukin (IL)-4 and IL-13 to the epithelial-mesenchymal trophic unit in asthma, Am J Respir Cell Mol Biol, 25, 385, 10.1165/ajrcmb.25.3.4437 Kraft, 2001, IL-4, IL-13, and dexamethasone augment fibroblast proliferation in asthma, J Allergy Clin Immunol, 107, 602, 10.1067/mai.2001.113760 Takayama, 2006, Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals, J Allergy Clin Immunol, 118, 98, 10.1016/j.jaci.2006.02.046 Zheng, 2000, Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema, J Clin Invest, 106, 1081, 10.1172/JCI10458 Chen, 2005, IL-11 receptor alpha in the pathogenesis of IL-13-induced inflammation and remodeling, J Immunol, 174, 2305, 10.4049/jimmunol.174.4.2305 Shim, 2006, Role of 5-lipoxygenase in IL-13-induced pulmonary inflammation and remodeling, J Immunol, 177, 1918, 10.4049/jimmunol.177.3.1918 Lee, 2006, ERK1/2 mitogen-activated protein kinase selectively mediates IL-13-induced lung inflammation and remodeling in vivo, J Clin Invest, 116, 163, 10.1172/JCI25711 Homer, 2002, Pulmonary type II cell hypertrophy and pulmonary lipoproteinosis are features of chronic IL-13 exposure, Am J Physiol Lung Cell Mol Physiol, 283, L52, 10.1152/ajplung.00438.2001 Blackburn, 2003, Adenosine mediates IL-13-induced inflammation and remodeling in the lung and interacts in an IL-13-adenosine amplification pathway, J Clin Invest, 112, 332, 10.1172/JCI200316815 Corne, 2000, IL-13 stimulates vascular endothelial cell growth factor and protects against hyperoxic acute lung injury, J Clin Invest, 106, 783, 10.1172/JCI9674 Zhu, 2002, IL-13-induced chemokine responses in the lung: role of CCR2 in the pathogenesis of IL-13-induced inflammation and remodeling, J Immunol, 168, 2953, 10.4049/jimmunol.168.6.2953 Zhu, 2004, Acidic mammalian chitinase in asthmatic Th2 inflammation and IL-13 pathway activation, Science, 304, 1678, 10.1126/science.1095336 Horie, 1997, Interleukin-13 but not interleukin-4 prolongs eosinophil survival and induces eosinophil chemotaxis, Intern Med, 36, 179, 10.2169/internalmedicine.36.179 Zhen, 2007, IL-13 and epidermal growth factor receptor have critical but distinct roles in epithelial cell mucin production, Am J Respir Cell Mol Biol, 36, 244, 10.1165/rcmb.2006-0180OC Booth, 2007, IL-13-induced proliferation of airway epithelial cells: mediation by intracellular growth factor mobilization and ADAM17, Respir Res, 8, 51, 10.1186/1465-9921-8-51 Bosse, 2008, Interleukin-4 and interleukin-13 enhance human bronchial smooth muscle cell proliferation, Int Arch Allergy Immunol, 146, 138, 10.1159/000113517 Parameswaran, 2007, Modulation of human airway smooth muscle migration by lipid mediators and Th-2 cytokines, Am J Respir Cell Mol Biol, 37, 240, 10.1165/rcmb.2006-0172OC Matsukura, 2001, Interleukin-13 upregulates eotaxin expression in airway epithelial cells by a STAT6-dependent mechanism, Am J Respir Cell Mol Biol, 24, 755, 10.1165/ajrcmb.24.6.4351 Li, 2010, Genome-wide association study of asthma identifies RAD50-IL13 and HLA-DR/DQ regions, J Allergy Clin Immunol, 125, 328, 10.1016/j.jaci.2009.11.018 Howard, 2002, Gene-gene interaction in asthma: IL4RA and IL13 in a Dutch population with asthma, Am J Hum Genet, 70, 230, 10.1086/338242 Konstantinidis, 2007, Genetic association studies of interleukin-13 receptor alpha1 subunit gene polymorphisms in asthma and atopy, Eur Respir J, 30, 40, 10.1183/09031936.00025706 2007, Expert panel report 3 (EPR-3): guidelines for the diagnosis and management of asthma—summary report 2007, J Allergy Clin Immunol, 120, S94 Howarth, 1995, The airway inflammatory response in allergic asthma and its relationship to clinical disease, Allergy, 50, 13, 10.1111/j.1398-9995.1995.tb02730.x McGrath, 2012, A large subgroup of mild-to-moderate asthma is persistently non-eosinophilic, Am J Respir Crit Care Med, 185, 612, 10.1164/rccm.201109-1640OC Berry, 2007, Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma, Thorax, 62, 1043, 10.1136/thx.2006.073429 Wenzel, 1999, Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics, Am J Respir Crit Care Med, 160, 1001, 10.1164/ajrccm.160.3.9812110 Simpson, 2006, Inflammatory subtypes in asthma: assessment and identification using induced sputum, Respirology, 11, 54, 10.1111/j.1440-1843.2006.00784.x Porsbjerg, 2009, Inflammatory subtypes in asthma are related to airway hyperresponsiveness to mannitol and exhaled NO, J Asthma, 46, 606, 10.1080/02770900903015654 Hastie, 2010, Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes, J Allergy Clin Immunol, 125, 1028, 10.1016/j.jaci.2010.02.008 Scott, 2011, Airway inflammation is augmented by obesity and fatty acids in asthma, Eur Respir J, 38, 594, 10.1183/09031936.00139810 Boulet, 2006, Smoking and asthma: clinical and radiologic features, lung function, and airway inflammation, Chest, 129, 661, 10.1378/chest.129.3.661 Wark, 2002, Neutrophil degranulation and cell lysis is associated with clinical severity in virus-induced asthma, Eur Respir J, 19, 68, 10.1183/09031936.02.00226302 Essilfie, 2011, Haemophilus influenzae infection drives IL-17-mediated neutrophilic allergic airways disease, PLoS Pathog, 7, e1002244, 10.1371/journal.ppat.1002244 McCreanor, 2007, Respiratory effects of exposure to diesel traffic in persons with asthma, N Engl J Med, 357, 2348, 10.1056/NEJMoa071535 Wallace, 2011, Association between proximity to major roads and sputum cell counts, Can Respir J, 18, 13, 10.1155/2011/920734 Jatakanon, 1999, Neutrophilic inflammation in severe persistent asthma, Am J Respir Crit Care Med, 160, 1532, 10.1164/ajrccm.160.5.9806170 Loughlin, 2010, Neutrophilic inflammation is associated with altered airway hydration in stable asthmatics, Respir Med, 104, 29, 10.1016/j.rmed.2009.07.002 Cowan, 2010, Effects of steroid therapy on inflammatory cell subtypes in asthma, Thorax, 65, 384, 10.1136/thx.2009.126722 Haldar, 2008, Cluster analysis and clinical asthma phenotypes, Am J Respir Crit Care Med, 178, 218, 10.1164/rccm.200711-1754OC Moore, 2010, Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program, Am J Respir Crit Care Med, 181, 315, 10.1164/rccm.200906-0896OC 2000, Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions, Am J Respir Crit Care Med, 162, 2341, 10.1164/ajrccm.162.6.ats9-00 Fitzpatrick, 2011, Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program, J Allergy Clin Immunol, 127, 382, 10.1016/j.jaci.2010.11.015 Baines, 2011, Transcriptional phenotypes of asthma defined by gene expression profiling of induced sputum samples, J Allergy Clin Immunol, 127, 153, 10.1016/j.jaci.2010.10.024 Gupta, 2010, Quantitative analysis of high-resolution computed tomography scans in severe asthma subphenotypes, Thorax, 65, 775, 10.1136/thx.2010.136374 Woodruff, 2009, T-helper type 2-driven inflammation defines major subphenotypes of asthma, Am J Respir Crit Care Med, 180, 388, 10.1164/rccm.200903-0392OC Choy, 2011, Gene expression patterns of Th2 inflammation and intercellular communication in asthmatic airways, J Immunol, 186, 1861, 10.4049/jimmunol.1002568 Giovannini-Chami, 2012, Distinct epithelial gene expression phenotypes in childhood respiratory allergy, Eur Respir J, 39, 1197, 10.1183/09031936.00070511 Fahy, 1995, Comparison of samples collected by sputum induction and bronchoscopy from asthmatic and healthy subjects, Am J Respir Crit Care Med, 152, 53, 10.1164/ajrccm.152.1.7599862 Djukanovic, 2002, Standardised methodology of sputum induction and processing, Eur Respir J Suppl, 37, 1s, 10.1183/09031936.02.00000102 Green, 2002, Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial, Lancet, 360, 1715, 10.1016/S0140-6736(02)11679-5 Jayaram, 2006, Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations, Eur Respir J, 27, 483, 10.1183/09031936.06.00137704 Chlumsky, 2006, Strategy aimed at reduction of sputum eosinophils decreases exacerbation rate in patients with asthma, J Int Med Res, 34, 129, 10.1177/147323000603400202 Fleming, 2012, Use of sputum eosinophil counts to guide management in children with severe asthma, Thorax, 67, 193, 10.1136/thx.2010.156836 Bossley, 2012, Pediatric severe asthma is characterized by eosinophilia and remodeling without T(H)2 cytokines, J Allergy Clin Immunol, 129, 974, 10.1016/j.jaci.2012.01.059 Schleich, 2010, Exhaled nitric oxide thresholds associated with a sputum eosinophil count >/=3% in a cohort of unselected patients with asthma, Thorax, 65, 1039, 10.1136/thx.2009.124925 Berry, 2005, The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma, Clin Exp Allergy, 35, 1175, 10.1111/j.1365-2222.2005.02314.x Buchvald, 2005, Measurements of exhaled nitric oxide in healthy subjects age 4 to 17 years, J Allergy Clin Immunol, 115, 1130, 10.1016/j.jaci.2005.03.020 Olin, 2007, Fraction of exhaled nitric oxide at 50 mL/s: reference values for adult lifelong never-smokers, Chest, 131, 1852, 10.1378/chest.06-2928 Gratziou, 1999, Influence of atopy on exhaled nitric oxide in patients with stable asthma and rhinitis, Eur Respir J, 14, 897, 10.1034/j.1399-3003.1999.14d28.x Kharitonov, 1995, Acute and chronic effects of cigarette smoking on exhaled nitric oxide, Am J Respir Crit Care Med, 152, 609, 10.1164/ajrccm.152.2.7543345 Silkoff, 2001, Dose-response relationship and reproducibility of the fall in exhaled nitric oxide after inhaled beclomethasone dipropionate therapy in asthma patients, Chest, 119, 1322, 10.1378/chest.119.5.1322 Kharitonov, 1995, Allergen-induced late asthmatic reactions are associated with elevation of exhaled nitric oxide, Am J Respir Crit Care Med, 151, 1894, 10.1164/ajrccm.151.6.7767537 Harkins, 2004, Exhaled nitric oxide predicts asthma exacerbation, J Asthma, 41, 471, 10.1081/JAS-120033990 Smith, 2005, Use of exhaled nitric oxide measurements to guide treatment in chronic asthma, N Engl J Med, 352, 2163, 10.1056/NEJMoa043596 Corren, 2011, Lebrikizumab treatment in adults with asthma, N Engl J Med, 365, 1088, 10.1056/NEJMoa1106469 Dweik, 2010, Use of exhaled nitric oxide measurement to identify a reactive, at-risk phenotype among patients with asthma, Am J Respir Crit Care Med, 181, 1033, 10.1164/rccm.200905-0695OC Chow, 2012, Exhaled breath condensate (EBC) biomarkers in pulmonary fibrosis, J Breath Res, 6, 016004, 10.1088/1752-7155/6/1/016004 Yates, 2011, Non-invasive assessment of exhaled biomarkers in lung transplantation, J Breath Res, 5, 024001, 10.1088/1752-7155/5/2/024001 Kaneko, 1998, Biochemical reaction products of nitric oxide as quantitative markers of primary pulmonary hypertension, Am J Respir Crit Care Med, 158, 917, 10.1164/ajrccm.158.3.9802066 Keen, 2010, Low levels of exhaled nitric oxide are associated with impaired lung function in cystic fibrosis, Pediatr Pulmonol, 45, 241, 10.1002/ppul.21137 Horn, 1975, Total eosinophil counts in the management of bronchial asthma, N Engl J Med, 292, 1152, 10.1056/NEJM197505292922204 Ulrik, 1995, Mortality and markers of risk of asthma death among 1,075 outpatients with asthma, Chest, 108, 10, 10.1378/chest.108.1.10 Noga, 2003, Immunological and clinical changes in allergic asthmatics following treatment with omalizumab, Int Arch Allergy Immunol, 131, 46, 10.1159/000070434 Haldar, 2009, Mepolizumab and exacerbations of refractory eosinophilic asthma, N Engl J Med, 360, 973, 10.1056/NEJMoa0808991 Nair, 2009, Mepolizumab for prednisone-dependent asthma with sputum eosinophilia, N Engl J Med, 360, 985, 10.1056/NEJMoa0805435 Burrows, 1989, Association of asthma with serum IgE levels and skin-test reactivity to allergens, N Engl J Med, 320, 271, 10.1056/NEJM198902023200502 Sherrill, 1999, Total serum IgE and its association with asthma symptoms and allergic sensitization among children, J Allergy Clin Immunol, 104, 28, 10.1016/S0091-6749(99)70110-7 Kerstjens, 1995, Importance of total serum IgE for improvement in airways hyperresponsiveness with inhaled corticosteroids in asthma and chronic obstructive pulmonary disease. The Dutch CNSLD Study Group, Am J Respir Crit Care Med, 151, 360, 10.1164/ajrccm.151.2.7842192 Ahmad Al Obaidi, 2008, The predictive value of IgE as biomarker in asthma, J Asthma, 45, 654, 10.1080/02770900802126958 Zitnik, 2009, IL13 variants are associated with total serum IgE and early sensitization to food allergens in children with atopic dermatitis, Pediatr Allergy Immunol, 20, 551, 10.1111/j.1399-3038.2008.00815.x Tan, 2011, Safety of omalizumab in asthma, Expert Opin Drug Saf, 10, 463, 10.1517/14740338.2011.563840 Kuhl, 2012, Targeting IgE in asthma, Curr Opin Pulm Med, 18, 1, 10.1097/MCP.0b013e32834deebb Yuyama, 2002, Analysis of novel disease-related genes in bronchial asthma, Cytokine, 19, 287, 10.1006/cyto.2002.1972 Blanchard, 2008, Periostin facilitates eosinophil tissue infiltration in allergic lung and esophageal responses, Mucosal Immunol, 1, 289, 10.1038/mi.2008.15 Sidhu, 2010, Roles of epithelial cell-derived periostin in TGF-beta activation, collagen production, and collagen gel elasticity in asthma, Proc Natl Acad Sci U S A, 107, 14170, 10.1073/pnas.1009426107 Gordon, 2012, A protective role for periostin and TGF-beta in IgE-mediated allergy and airway hyperresponsiveness, Clin Exp Allergy, 42, 144, 10.1111/j.1365-2222.2011.03840.x Woodruff, 2007, Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids, Proc Natl Acad Sci U S A, 104, 15858, 10.1073/pnas.0707413104 Lopez-Guisa, 2012, Airway epithelial cells from asthmatic children differentially express proremodeling factors, J Allergy Clin Immunol, 129, 990, 10.1016/j.jaci.2011.11.035 Strunk, 2003, Relationship of exhaled nitric oxide to clinical and inflammatory markers of persistent asthma in children, J Allergy Clin Immunol, 112, 883, 10.1016/j.jaci.2003.08.014 Levesque, 2008, Determinants of exhaled nitric oxide levels in healthy, nonsmoking African American adults, J Allergy Clin Immunol, 121, 396, 10.1016/j.jaci.2007.09.031 Petsky, 2012, A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils), Thorax, 67, 199, 10.1136/thx.2010.135574 Gelb, 2012, In moderate-to-severe asthma patients monitoring exhaled nitric oxide during exacerbation is not a good predictor of spirometric response to oral corticosteroid, J Allergy Clin Immunol, 129, 1491, 10.1016/j.jaci.2012.03.036 Little, 2000, Non-invasive markers of airway inflammation as predictors of oral steroid responsiveness in asthma, Thorax, 55, 232, 10.1136/thorax.55.3.232 Yap, 2011, Can we predict sputum eosinophilia from clinical assessment in patients referred to an adult asthma clinic?, Intern Med J, 10.1111/j.1445-5994.2011.02565.x Busse, 2011, Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children, N Engl J Med, 364, 1005, 10.1056/NEJMoa1009705 Wenzel, 2007, Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies, Lancet, 370, 1422, 10.1016/S0140-6736(07)61600-6 Slager, 2010, IL-4 receptor alpha polymorphisms are predictors of a pharmacogenetic response to a novel IL-4/IL-13 antagonist, J Allergy Clin Immunol, 126, 875, 10.1016/j.jaci.2010.08.001 Slager, 2012, IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor alpha antagonist, J Allergy Clin Immunol, 10.1016/j.jaci.2012.03.030 Gauvreau, 2011, Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma, Am J Respir Crit Care Med, 183, 1007, 10.1164/rccm.201008-1210OC Kasaian, 2011, IL-13 antibodies influence IL-13 clearance in humans by modulating scavenger activity of IL-13Ralpha2, J Immunol, 187, 561, 10.4049/jimmunol.1100467 Leigh, 2002, Effects of montelukast and budesonide on airway responses and airway inflammation in asthma, Am J Respir Crit Care Med, 166, 1212, 10.1164/rccm.200206-509OC O'Byrne, 2009, Provoked models of asthma: what have we learnt?, Clin Exp Allergy, 39, 181, 10.1111/j.1365-2222.2008.03172.x Hodsman, 2012, A phase 1, randomized, placebo-controlled, dose-escalation study of an anti-IL-13 monoclonal antibody in healthy subjects and mild asthmatics, Br J Clin Pharmacol, 10.1111/j.1365-2125.2012.04334.x Corren, 2010, A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma, Am J Respir Crit Care Med, 181, 788, 10.1164/rccm.200909-1448OC Singh, 2010, A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma, BMC Pulm Med, 10, 3, 10.1186/1471-2466-10-3 Blanchard, 2005, Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-interleukin-13 antibody (CAT-354), Clin Exp Allergy, 35, 1096, 10.1111/j.1365-2222.2005.02299.x Kaur, 2006, Mast cells express IL-13R alpha 1: IL-13 promotes human lung mast cell proliferation and Fc epsilon RI expression, Allergy, 61, 1047, 10.1111/j.1398-9995.2006.01139.x May, 2012, Preclinical development of CAT-354, an IL-13-neutralising antibody, for the treatment of severe uncontrolled asthma, Br J Pharmacol, 166, 177, 10.1111/j.1476-5381.2011.01659.x May, 2012, Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma, Br J Pharmacol, 166, 177, 10.1111/j.1476-5381.2011.01659.x Akimoto, 1998, Abrogation of bronchial eosinophilic inflammation and airway hyperreactivity in signal transducers and activators of transcription (STAT)6-deficient mice, J Exp Med, 187, 1537, 10.1084/jem.187.9.1537 Darcan-Nicolaisen, 2009, Small interfering RNA against transcription factor STAT6 inhibits allergic airway inflammation and hyperreactivity in mice, J Immunol, 182, 7501, 10.4049/jimmunol.0713433 McCusker, 2007, Inhibition of experimental allergic airways disease by local application of a cell-penetrating dominant-negative STAT-6 peptide, J Immunol, 179, 2556, 10.4049/jimmunol.179.4.2556